Dr Xiaowei Wang
Diploma of Cardiac Technology | BSc(Hons) | PhD (Monash University) | FCSANZ | FAHA
Dr Xiaowei Wang heads the Molecular Imaging and Theranostics laboratory at the Baker Heart and Diabetes Institute. She also co-chairs the Atherothrombosis Program and the Mentoring Committee at the Institute.
Dr Wang was trained as a sonographer for echocardiography prior to her research career; therefore her work has a strong focus on translational cardiovascular research. Dr Wang’s work spans across several scientific fields, including physics, chemistry, biology and biotechnology, and uniquely combines both basic research and translational development of future diagnostic tools to be used in patients. Her research focuses on preclinical molecular imaging across a range of technologies, such as MRI, ultrasound, PET, microCT, fluorescence and photoacoustic imaging. Dr Wang has employed these technologies for both diagnostic and theranostic (simultaneous diagnosis, therapy and monitoring of treatment efficacy) purposes. Her other research interests are targeted drug therapy and the use of micro/nanoparticles for targeted delivery of drugs.
Dr Wang has presented her work at numerous conferences. She has been awarded 15 international and 12 national travel grants, 14 Young Investigator Awards and 18 prizes. Dr Wang is also a founding member of the Australian Society of Molecular Imaging (ASMI), established in 2013, and was elected as President. She is the Australian Representative for the both Federation of Asian Societies of Molecular Imaging (FASMI) as well as the World Molecular Imaging Society (WMIS). Dr Wang is the President-elect of FASMI and will be President in 2021. She is also on the Leadership Committee of the WMIS Women in Molecular Imaging Network.